Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1911
Title: Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring
Authors: Chan, Matthew M K ;Sabanathan, D.;Zhang, A.;Fox, P.;Coulter, S.;Gebski, V.;Balakrishnar, B.;Liddle, C.;Gurney, H.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Aug-2017
Source: 80(2):385-393
Journal title: Cancer Chemotherapy & Pharmacology
Department: Medical Oncology
Central Coast Cancer Centre
Abstract: PURPOSE: Dose individualization of sunitinib has been proposed using therapeutic drug monitoring (TDM) or toxicity-adjusted dose (TAD). We prospectively studied aspects of TDM and TAD to inform future trials, namely (1) intrapatient variability (CV) of sunitinib and (2) feasibility of a TAD protocol. METHODS: Sunitinib dose was adjusted to ensure grade 1 or 2 toxicity on 10-20 days of each 42-day cycle. Total trough levels (TTL) C (min) of sunitinib and its active metabolite were measured every 6 weeks. RESULTS: In 45 patients with mRCC, 283 TTL samples were assayed over a median 30 weeks (6-108 weeks). Fifteen patients (33%) had an intrapatient CV of >25% in TTL. Ninety-one percent achieved target toxicity with a final sunitinib dose of 25 mg (18%), 37.5 mg (27%), 50 mg (50%), and 62.5 or 75 mg (7%). TTL C (min) was <50, 50-100, and >100 ng/mL in 7 (15%), 31 (69%), and 7 patients (15.5%), respectively. The median overall survival was 32 months. CONCLUSIONS: Sunitinib level has minimal variability in the majority of patients on stable dose. A subset of patients had a significant intrapatient variation, so we recommend two samples 4 to 6 months apart. TAD is feasible for dosing sunitinib and showed a favourable outcome.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1911
DOI: 10.1007/s00280-017-3362-1
Pubmed: https://pubmed.ncbi.nlm.nih.gov/28667354/
ISSN: 0344-5704
Publicaton type: Journal Article
Keywords: Cancer
Drug Therapy
Appears in Collections:Oncology / Cancer

Show full item record

Page view(s)

10
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.